CMPS compared with RARE: revenue, margins and what each company keeps, and the suppliers and customers both name

CMPSCOMPASS Pathways plc

Mkt capRevenueRevenue

RAREUltragenyx Pharmaceutical Inc.

Mkt capRevenueRevenue

Compare

CMPSCOMPASS Pathways plc

RAREUltragenyx Pharmaceutical Inc.

Price

Mkt cap

Revenue

Revenue flow Supply chain Price Co-movers Event sensitivity Earnings history

Save comparison

Earnings history

News Findings Companies A–Z Pricing Methodology Sources Corrections About Terms

Not investment advice. Not a broker-dealer. Indices shown as ETF proxies. Supply-chain data CC BY 4.0; market data not redistributable.

Listed on One’s Vibe · live-checked · Oct ’26

Desk News Calendar Saved

Earnings history

last 4 reports each · paired by recencyMethod ›

CMPS

No earnings history for CMPS.

RARE1 of 4 reports

0 of 1at or beyond implied

Reportimpliedrealized× implied

Q2 FY26±16.4%▼−3.41%×0.21

= impliedCMPS realized, solidRARE realized, hatchedOne scale, both sides: full bar = 17%× = |realized| ÷ impliedSource: market data

CMPSCOMPASS Pathways plc

11.57▼−5.09%· post 11.62

Mkt cap$1.6BRevenue—Revenue—

RAREUltragenyx Pharmaceutical Inc.

16.10▼−4.05%· post 16.06

ClosedOct 30 '26

Mkt cap$1.6BRevenue$214MQ2 FY26Revenue$673MFY25

Compare

ClosedOct 30 '26

CMPSCOMPASS Pathways plc

RAREUltragenyx Pharmaceutical Inc.

11.57▼−5.09%post 11.62

Price

16.10▼−4.05%post 16.06

$1.6B

Mkt cap

$1.6B

—

Revenue

$214MQ2 FY26

—

Revenue

$673MFY25

CMPS11.57▼−5.09%vsRARE16.10▼−4.05%ClosedOct 30 '26